Cat. #160517
CS-5d Bcr-Abl and Btk small molecule kinase inhibitors
Cat. #: 160517
Sub-type: Inhibitor
Availability: Please enquire for quantities and pricing
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Cristian Salas
Institute: Pontificia Universidad Catolica de Chile
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Tool name: CS-5d Bcr-Abl and Btk small molecule kinase inhibitors
- Cancer: Blood cancer
- Cancers detailed: Leukemia
- Research fields: Cancer
- Molecular formula: C26H28F2N8
- Tool sub type: Inhibitor
- Primary target: Bcr-Abl and Btk kinases
- Description: This compound inhibits in nanomolar scale for Bcr-Abl (40 nM) and sub-micromolar scale for Btk kinases (0,58 M), both are related to the genesis and progression of myeloid and lymphoid leukaemia, respectively
- Purpose: Inhibitor
- Iupac: 9-(Cyclopropylmethyl)-N6-(3,4-difluorophenyl)-N2-(4-(4-methylpiperazin-1-yl)phenyl)-9H-purine-2,6-diamine
- Molecular weight: 490.5509
- Solubility: DMSO
Handling
- Purity: 490.5509 g/mol
- Storage conditions: Away from UV light
- Shipping conditions: Dry Ice
Target Details
- Primary target: Bcr-Abl and Btk kinases
Related Tools
- Related tools: CS-5c Bcr-Abl and Btk small molecule kinase inhibitors
References
- Bertrand et al. 2020. Bioorg Chem. 94:103361. PMID: 31699386.